Symbols / SBFM Stock $1.00 +2.03% Sunshine Biopharma, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
SBFM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Steve N. Slilaty Ph.D.
Exch · Country NCM · United States
Market Cap 4.91M
Enterprise Value -3.39M
Income -5.98M
Sales 36.31M
FCF (ttm) -4.63M
Book/sh 4.69
Cash/sh 1.86
Employees 50
Insider 10d —
IPO Feb 15, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.20
Forward P/E 0.01
PEG —
P/S 0.14
P/B 0.21
P/C —
EV/EBITDA 0.82
EV/Sales -0.09
Quick Ratio 1.95
Current Ratio 4.17
Debt/Eq 3.53
LT Debt/Eq —
EPS (ttm) -1.44
EPS next Y 199.80
EPS Growth —
Revenue Growth -10.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-03
Earnings (prior) 2026-04-03
ROA -9.23%
ROE -25.68%
ROIC —
Gross Margin 33.76%
Oper. Margin -19.33%
Profit Margin -16.46%
Shs Outstand 4.91M
Shs Float 4.80M
Insider Own 0.04%
Instit Own 5.24%
Short Float 2.74%
Short Ratio 3.99
Short Interest 134.38K
52W High 2.43
vs 52W High -58.85%
52W Low 0.95
vs 52W Low 4.93%
Beta 1.60
Impl. Vol. —
Rel Volume 1.14
Avg Volume 36.79K
Volume 41.83K
Target (mean) $5.60
Tgt Median $5.60
Tgt Low $5.60
Tgt High $5.60
# Analysts 1
Recom None
Prev Close $0.98
Price $1.00
Change 2.03%
About

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.60
Mean price target
2. Current target
$1.00
Latest analyst target
3. DCF / Fair value
$-17.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.00
Low
$5.60
High
$5.60
Mean
$5.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-08 reit Aegis Capital Buy → Buy $7
2024-12-05 reit Aegis Capital Buy → Buy $15
2023-08-07 init Aegis Capital — → Buy $3
News
RSS: Latest SBFM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 NATAN DAVID Director — 100,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
36.31
+4.11%
34.87
+44.75%
24.09
+454.42%
4.35
Operating Revenue
36.31
+4.11%
34.87
+44.75%
24.09
+454.42%
4.35
Cost Of Revenue
24.05
-0.64%
24.20
+53.64%
15.75
+494.69%
2.65
Reconciled Cost Of Revenue
24.05
-0.64%
24.20
+53.64%
15.75
+494.69%
2.65
Gross Profit
12.26
+14.86%
10.67
+27.95%
8.34
+391.53%
1.70
Operating Expense
16.73
+1.53%
16.48
+25.58%
13.12
+26.55%
10.37
Research And Development
0.60
-35.29%
0.93
-49.68%
1.86
+128.59%
0.81
Selling General And Administration
15.33
+2.62%
14.94
+37.93%
10.83
+14.26%
9.48
Selling And Marketing Expense
1.14
+21.66%
0.94
+28.06%
0.73
+27.01%
0.58
General And Administrative Expense
14.18
+1.34%
14.00
+38.65%
10.10
+13.43%
8.90
Salaries And Wages
7.67
-5.58%
8.12
+32.81%
6.11
-3.81%
6.35
Other Gand A
6.52
+10.90%
5.88
+47.61%
3.98
+56.47%
2.55
Total Expenses
40.78
+0.24%
40.69
+40.89%
28.88
+121.80%
13.02
Operating Income
-4.48
+22.94%
-5.81
-21.46%
-4.79
+44.83%
-8.67
Total Operating Income As Reported
-6.23
-7.14%
-5.81
-21.46%
-4.79
+82.28%
-27.00
EBITDA
-5.62
-9.44%
-5.14
-34.31%
-3.82
+85.54%
-26.45
Normalized EBITDA
-3.87
+24.09%
-5.09
-33.17%
-3.82
+52.96%
-8.13
Reconciled Depreciation
0.33
+48.56%
0.22
+49.87%
0.15
+492.72%
0.03
EBIT
-5.95
-11.07%
-5.36
-34.90%
-3.97
+84.99%
-26.47
Total Unusual Items
-1.76
-3883.17%
-0.04
-17892.65%
-0.00
+100.00%
-18.32
Total Unusual Items Excluding Goodwill
-1.76
-3883.17%
-0.04
-17892.65%
-0.00
+100.00%
-18.32
Special Income Charges
-1.76
0.00
0.00
+100.00%
-18.32
Other Special Charges
—
—
—
-0.01
Impairment Of Capital Assets
1.75
0.00
0.00
-100.00%
18.33
Net Income
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Pretax Income
-5.95
-10.89%
-5.37
-30.60%
-4.11
+84.49%
-26.51
Net Non Operating Interest Income Expense
0.28
-42.35%
0.49
-27.78%
0.67
+40.78%
0.48
Interest Expense Non Operating
0.00
-100.00%
0.01
-93.61%
0.14
+248.39%
0.04
Net Interest Income
0.28
-42.35%
0.49
-27.78%
0.67
+40.78%
0.48
Interest Expense
0.00
-100.00%
0.01
-93.61%
0.14
+248.39%
0.04
Interest Income Non Operating
0.28
-43.37%
0.50
-38.91%
0.81
+56.56%
0.52
Interest Income
0.28
-43.37%
0.50
-38.91%
0.81
+56.56%
0.52
Other Income Expense
-1.76
-3883.17%
-0.04
-17892.65%
-0.00
+100.00%
-18.32
Gain On Sale Of Security
0.00
+105.99%
-0.04
-17892.65%
-0.00
+48.53%
-0.00
Tax Provision
0.02
+109.20%
-0.23
-159.43%
0.40
+69.38%
0.23
Tax Rate For Calcs
0.00
+380.07%
0.00
-79.17%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.37
-19022.04%
-0.00
-3647.92%
-0.00
+100.00%
-3.85
Net Income Including Noncontrolling Interests
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Net Income From Continuing Operation Net Minority Interest
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Net Income From Continuing And Discontinued Operation
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Net Income Continuous Operations
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Normalized Income
-4.59
+9.89%
-5.09
-13.01%
-4.51
+63.29%
-12.27
Net Income Common Stockholders
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Diluted EPS
—
-7.32
+97.92%
-351.36
+90.02%
-3,520.00
Basic EPS
—
-7.32
+97.92%
-351.36
+90.02%
-3,520.00
Basic Average Shares
—
0.70
+5371.73%
0.01
+68.97%
0.01
Diluted Average Shares
—
0.70
+5371.73%
0.01
+68.97%
0.01
Diluted NI Availto Com Stockholders
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Depreciation Amortization Depletion Income Statement
0.33
+48.56%
0.22
+49.87%
0.15
+492.72%
0.03
Depreciation And Amortization In Income Statement
0.33
+48.56%
0.22
+49.87%
0.15
+492.72%
0.03
Depreciation Income Statement
—
—
—
—
Gain On Sale Of PPE
-0.01
0.00
—
—
Other Taxes
0.47
+21.27%
0.39
+33.57%
0.29
+424.57%
0.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
30.08
-1.57%
30.56
+11.75%
27.35
-6.49%
29.24
Current Assets
26.85
+3.42%
25.97
+4.32%
24.89
-8.87%
27.31
Cash Cash Equivalents And Short Term Investments
9.12
-5.81%
9.69
-40.55%
16.29
-25.35%
21.83
Cash And Cash Equivalents
9.12
-5.81%
9.69
-40.55%
16.29
-25.35%
21.83
Cash Financial
9.12
-5.81%
9.69
-40.55%
16.29
-25.35%
21.83
Receivables
3.46
-10.56%
3.87
+51.56%
2.55
+33.48%
1.91
Accounts Receivable
3.46
-10.56%
3.87
+51.56%
2.55
+33.48%
1.91
Inventory
13.47
+19.45%
11.28
+96.66%
5.73
+74.31%
3.29
Finished Goods
13.47
+19.45%
11.28
+96.66%
5.73
—
Prepaid Assets
0.80
-29.55%
1.13
+264.88%
0.31
+9.44%
0.28
Total Non Current Assets
3.21
-30.22%
4.59
+86.98%
2.46
+27.20%
1.93
Net PPE
1.32
-11.19%
1.48
+46.36%
1.01
-12.30%
1.15
Gross PPE
1.83
+0.58%
1.82
+51.22%
1.20
-2.89%
1.24
Accumulated Depreciation
-0.51
-52.40%
-0.34
-77.13%
-0.19
-126.71%
-0.08
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.78
-16.79%
0.94
+44.72%
0.65
—
Machinery Furniture Equipment
0.62
+36.00%
0.46
+24.86%
0.37
+16.11%
0.32
Other Properties
0.34
-0.42%
0.34
+96.02%
0.17
-81.38%
0.92
Leases
0.09
+4.98%
0.09
+399.92%
0.02
0.00
Goodwill And Other Intangible Assets
1.89
-37.43%
3.02
+109.08%
1.44
+85.91%
0.78
Non Current Deferred Assets
0.00
-100.00%
0.09
0.00
—
Non Current Deferred Taxes Assets
0.00
-100.00%
0.09
0.00
—
Total Liabilities Net Minority Interest
7.04
-0.27%
7.06
+14.99%
6.14
-19.39%
7.62
Current Liabilities
6.44
+2.04%
6.31
+13.74%
5.55
-19.90%
6.93
Payables And Accrued Expenses
6.23
+1.98%
6.11
+12.41%
5.43
-20.19%
6.81
Payables
6.23
+1.98%
6.11
+12.41%
5.43
-20.19%
6.81
Accounts Payable
5.66
+2.19%
5.54
+114.39%
2.59
-7.75%
2.80
Other Payable
0.30
+0.00%
0.30
-88.39%
2.55
-29.85%
3.63
Current Accrued Expenses
—
—
—
0.00
Total Tax Payable
0.27
+0.00%
0.27
-10.54%
0.30
-19.65%
0.37
Income Tax Payable
0.27
+0.00%
0.27
-10.54%
0.30
-19.65%
0.37
Current Debt And Capital Lease Obligation
0.22
+3.79%
0.21
+75.07%
0.12
-3.54%
0.12
Current Debt
—
—
—
3.63
Other Current Borrowings
—
—
—
3.63
Current Capital Lease Obligation
0.22
+3.79%
0.21
+75.07%
0.12
-3.54%
0.12
Other Current Liabilities
—
—
—
0.12
Total Non Current Liabilities Net Minority Interest
0.60
-19.86%
0.74
+26.70%
0.59
-14.23%
0.69
Long Term Debt And Capital Lease Obligation
0.60
-19.86%
0.74
+38.16%
0.54
-16.07%
0.64
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
0.60
-19.86%
0.74
+38.16%
0.54
-16.07%
0.64
Non Current Deferred Liabilities
—
0.00
-100.00%
0.05
+13.24%
0.04
Non Current Deferred Taxes Liabilities
—
0.00
-100.00%
0.05
+13.24%
0.04
Stockholders Equity
23.04
-1.97%
23.50
+10.81%
21.21
-1.94%
21.63
Common Stock Equity
23.03
-1.97%
23.49
+10.76%
21.21
-1.94%
21.63
Capital Stock
0.02
+14.92%
0.02
+1436.49%
0.00
-95.70%
0.02
Common Stock
0.00
+90.12%
0.00
+18328.57%
0.00
-99.94%
0.02
Preferred Stock
0.01
+0.00%
0.01
+1200.00%
0.00
+0.00%
0.00
Share Issued
4.91
+90.15%
2.58
+18313.49%
0.01
+24.09%
0.01
Ordinary Shares Number
4.91
+90.15%
2.58
+18313.49%
0.01
+24.09%
0.01
Additional Paid In Capital
98.10
+5.08%
93.35
+10.59%
84.42
+4.42%
80.84
Retained Earnings
-75.02
-8.65%
-69.04
-8.03%
-63.91
-7.59%
-59.40
Gains Losses Not Affecting Retained Earnings
-0.07
+92.13%
-0.83
-219.23%
0.70
+330.10%
0.16
Other Equity Adjustments
-0.07
+92.13%
-0.83
-219.23%
0.70
+330.10%
0.16
Total Equity Gross Minority Interest
23.04
-1.97%
23.50
+10.81%
21.21
-1.94%
21.63
Total Capitalization
23.04
-1.97%
23.50
+10.81%
21.21
-1.94%
21.63
Working Capital
20.41
+3.86%
19.65
+1.62%
19.34
-5.12%
20.38
Invested Capital
23.03
-1.97%
23.49
+10.76%
21.21
-1.94%
21.63
Total Debt
0.81
-14.70%
0.95
+44.82%
0.66
-14.05%
0.77
Capital Lease Obligations
0.81
-14.70%
0.95
+44.82%
0.66
-14.05%
0.77
Net Tangible Assets
21.15
+3.26%
20.48
+3.63%
19.76
-5.22%
20.85
Tangible Book Value
21.14
+3.26%
20.47
+3.57%
19.76
-5.22%
20.85
Current Notes Payable
—
—
—
—
Interest Payable
—
—
—
0.00
Preferred Stock Equity
0.01
+0.00%
0.01
+1200.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.33
+57.44%
-12.52
-42.73%
-8.78
-67.20%
-5.25
Cash Flow From Continuing Operating Activities
-5.33
+57.44%
-12.52
-42.73%
-8.78
-67.20%
-5.25
Net Income From Continuing Operations
-5.98
-16.39%
-5.13
-13.94%
-4.51
+83.15%
-26.74
Depreciation Amortization Depletion
0.33
+48.56%
0.22
+49.87%
0.15
+492.72%
0.03
Depreciation
—
0.15
+32.35%
0.11
—
Amortization Cash Flow
—
0.08
+100.30%
0.04
—
Depreciation And Amortization
0.33
+48.56%
0.22
+49.87%
0.15
+492.72%
0.03
Amortization Of Intangibles
—
0.08
+100.30%
0.04
—
Other Non Cash Items
—
-2.24
—
-0.01
Asset Impairment Charge
1.75
0.00
0.00
-100.00%
18.33
Deferred Tax
—
0.00
0.00
—
Deferred Income Tax
—
0.00
0.00
—
Operating Gains Losses
0.01
—
—
0.00
Net Foreign Currency Exchange Gain Loss
—
—
0.00
-100.00%
0.00
Gain Loss On Sale Of PPE
0.01
0.00
—
—
Change In Working Capital
-1.45
+73.09%
-5.37
-21.64%
-4.42
-240.06%
3.15
Change In Receivables
-0.12
+95.03%
-2.34
-293.54%
-0.59
-13.28%
-0.52
Changes In Account Receivables
-0.12
+95.03%
-2.34
-293.54%
-0.59
-13.28%
-0.52
Change In Inventory
-1.64
+72.74%
-6.01
-153.93%
-2.37
-5603.45%
0.04
Change In Prepaid Assets
0.48
+332.08%
-0.21
-879.84%
-0.02
-125.52%
0.08
Change In Payables And Accrued Expense
-0.19
-105.99%
3.17
+320.66%
-1.44
-140.45%
3.55
Change In Accrued Expense
—
—
0.00
+100.00%
-0.05
Change In Payable
-0.19
-105.99%
3.17
+320.66%
-1.44
-139.91%
3.60
Change In Account Payable
-0.19
-104.77%
3.98
+392.04%
-1.36
-140.61%
3.36
Change In Other Current Assets
0.20
+159.68%
-0.34
—
—
Change In Other Current Liabilities
-0.19
-153.90%
0.35
—
—
Investing Cash Flow
-0.84
+57.75%
-1.98
-201.66%
-0.66
+95.51%
-14.62
Cash Flow From Continuing Investing Activities
-0.84
+57.75%
-1.98
-201.66%
-0.66
+95.51%
-14.62
Cash From Discontinued Investing Activities
—
—
—
—
Net PPE Purchase And Sale
-0.17
+89.47%
-1.66
-3434.25%
0.05
+130.94%
-0.16
Purchase Of PPE
-0.17
+89.47%
-1.66
-1914.63%
-0.08
+57.60%
-0.19
Sale Of PPE
—
—
0.13
+295.31%
0.03
Capital Expenditure
-0.84
+57.75%
-1.98
-151.15%
-0.79
-158.40%
-0.30
Net Business Purchase And Sale
—
—
0.00
+100.00%
-14.35
Purchase Of Business
—
—
0.00
+100.00%
-14.35
Net Intangibles Purchase And Sale
-0.66
-105.37%
-0.32
+54.34%
-0.71
-535.81%
-0.11
Purchase Of Intangibles
-0.66
-105.37%
-0.32
+54.34%
-0.71
-535.81%
-0.11
Financing Cash Flow
4.75
-46.90%
8.94
+161.02%
3.43
-91.32%
39.47
Cash Flow From Continuing Financing Activities
4.75
-46.90%
8.94
+161.02%
3.43
-91.32%
39.47
Net Issuance Payments Of Debt
—
0.35
+376.16%
-0.13
+93.48%
-1.93
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
0.00
+100.00%
-1.90
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
0.00
+100.00%
-1.90
Net Long Term Debt Issuance
—
0.35
+376.16%
-0.13
+93.48%
-1.93
Net Common Stock Issuance
1.83
-66.03%
5.38
+51.71%
3.55
-88.28%
30.27
Common Stock Payments
0.00
+100.00%
-3.14
-480.19%
-0.54
-446.61%
-0.10
Repurchase Of Capital Stock
0.00
+100.00%
-3.14
-480.19%
-0.54
-446.61%
-0.10
Proceeds From Stock Option Exercised
2.92
-17.96%
3.56
+101522.27%
0.00
-99.97%
13.19
Net Other Financing Charges
—
—
—
-2.06
Changes In Cash
-1.42
+74.49%
-5.56
+7.38%
-6.01
-130.65%
19.60
Effect Of Exchange Rate Changes
0.86
+182.02%
-1.04
-321.23%
0.47
+156.42%
0.18
Beginning Cash Position
9.69
-40.55%
16.29
-25.35%
21.83
+967.22%
2.05
End Cash Position
9.12
-5.81%
9.69
-40.55%
16.29
-25.35%
21.83
Free Cash Flow
-6.17
+57.48%
-14.50
-51.67%
-9.56
-72.21%
-5.55
Interest Paid Supplemental Data
0.00
-100.00%
0.01
0.00
-100.00%
0.05
Income Tax Paid Supplemental Data
0.00
-100.00%
0.58
0.00
0.00
Change In Income Tax Payable
0.00
+100.00%
-0.81
-1008.69%
-0.07
-130.23%
0.24
Change In Interest Payable
—
—
0.00
+100.00%
-0.05
Change In Tax Payable
0.00
+100.00%
-0.81
-1008.69%
-0.07
-130.23%
0.24
Common Stock Issuance
1.83
-78.54%
8.52
+108.41%
4.09
-86.53%
30.37
Issuance Of Capital Stock
1.83
-78.54%
8.52
+108.41%
4.09
-86.53%
30.37
Net Preferred Stock Issuance
—
—
—
-0.10
Preferred Stock Payments
—
—
—
-0.10
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category